These results are consistent with the CELESTIAL trial of patients with advanced HCC, which demonstrated median OS and PFS of 8.5 and 3.7 months, respectively, in patients who received cabozantinib and progressed to CP-B liver function by week 8 of treatment (both outcomes were analyzed from randomization).4 These results suggest that continuation of systemic therapies may be a viable option for these patients, who have poor prognosis and limited treatment options. Here, CPB1 is linked to hepatocellular carcinoma.